In conclusion, this study provides real‐world evidence that AICT improves PFS and OSpTKI in patients with advanced‐stage EGFR‐mutated NSCLC following progression on frontline EGFR‐TKI therapies. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.